A recent study published in Brain challenges long-held assumptions about Alzheimer’s disease treatment. Researchers at the ...

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated ...

A study by the team of Prof. Kristel Sleegers (VIB-UAntwerp), published in Acta Neuropathologica, has offered new insights ...

The chronic neurodegenerative disease Alzheimer’s disease (AD) generally begins at around 60 years old, progressively ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the ...

The company begins Phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ...

New theories suggest Alzheimer's may involve autoimmunity, with beta-amyloid linked to immune response misfires.

"Amyloid immunotherapy has consistently shown an increase in brain volume loss – leading to concerns in the media and medical ...

It sees advancements with new drug classes like cholinesterase inhibitors. The global Alzheimer's disease therapeutics market ...

Belly fat, also known as visceral fat, may contribute to brain atrophy and early markers of Alzheimer’s disease, new research ...

Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.

Black older adults who frequently attend religious services are significantly less likely to develop Alzheimer’s or related ...